Droplet Digital PCR Assay for MYD88L265P: Clinical Applications in Waldenström Macroglobulinemia
Open Access
- 3 January 2020
- journal article
- editorial
- Published by Wiley in HemaSphere
- Vol. 4 (1), e324
- https://doi.org/10.1097/hs9.0000000000000324
Abstract
No abstract availableFunding Information
- Fondazione CRT (2016.0677, 2018.1284)
- Leukemia and Lymphoma Society
This publication has 16 references indexed in Scilit:
- Diagnosis and Management of Waldenström MacroglobulinemiaJAMA Oncology, 2017
- Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathiesEmergencias, 2016
- Treatment recommendations from the Eighth International Workshop on Waldenström’s MacroglobulinemiaBlood, 2016
- The 2016 revision of the World Health Organization classification of lymphoid neoplasmsBlood, 2016
- Survival outcomes of secondary cancers in patients with waldenström macroglobulinemia: An analysis of the SEER databaseAmerican Journal of Hematology, 2015
- Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemiaLeukemia & Lymphoma, 2015
- Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemiaBlood, 2014
- A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemiaBlood, 2013
- MYD88 L265P Somatic Mutation in Waldenström's MacroglobulinemiaThe New England Journal of Medicine, 2012
- The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applicationsBlood, 2011